Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Coya Therapeutics, Inc. ( (COYA) ) has provided an update.
Coya Therapeutics reported its financial results for the second quarter of 2025, highlighting significant corporate developments. The company submitted additional nonclinical data to the FDA to support the COYA 302 Phase 2 trial for ALS and published research on Parkinson’s Disease progression. Coya announced a new U.S. patent for a liquid IL-2 formulation and anticipates several catalysts, including FDA decisions and data releases, which could impact its strategic positioning in the biotechnology sector. Financially, Coya reported a net loss of $6.1 million for the quarter, with cash and cash equivalents of $29.8 million, and a decrease in collaboration revenues compared to the previous year.
The most recent analyst rating on (COYA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
Coya Therapeutics, Inc. has a mixed outlook. Strong clinical progress and financial stability from a debt-free balance sheet with cash reserves are significant positives. However, persistent profitability and cash flow challenges weigh heavily on the overall score. Technical indicators suggest moderate momentum, while valuation remains pressured by ongoing losses. The company’s strategic advancements and funding efforts are positive but need to translate into improved financial performance to enhance the stock’s appeal.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Coya Therapeutics, Inc., headquartered in Houston, TX, is a clinical-stage biotechnology company specializing in the development of treatments that leverage the biology of regulatory T cells (Tregs) to address systemic inflammation and neuroinflammation. The company’s investigational product pipeline focuses on restoring the anti-inflammatory and immunomodulatory functions of Tregs, targeting neurodegenerative, metabolic, and autoimmune diseases.
Average Trading Volume: 58,657
Technical Sentiment Signal: Hold
See more insights into COYA stock on TipRanks’ Stock Analysis page.